MONALISA® Ultra Type with Lidocaine – 1 × 1ml *SALE*

MONALISA® Ultra Type with Lidocaine – 1 × 1ml

Product Overview

MONALISA® Ultra Type with Lidocaine is a professional cross-linked Hyaluronic Acid (HA) dermal filler developed for advanced facial augmentation, deep volume restoration, structural support and contour enhancement.

Manufactured by GENOSS in South Korea, MONALISA® Ultra Type contains 24mg/ml cross-linked Hyaluronic Acid and 0.3% Lidocaine.

Featuring a large 900µm particle specification, Ultra Type is positioned as the largest-particle formulation within the core MONALISA® Soft, Mild, Hard and Ultra range.

Its dense gel characteristics are designed to provide greater structural support, projection and volume retention in appropriately selected treatment areas.

Unlike softer formulations developed for fine wrinkles or moderate soft tissue augmentation, MONALISA® Ultra Type is intended primarily for deeper volume restoration and advanced facial contouring.

The cross-linked HA gel provides an immediate physical volumising effect following appropriate placement, supporting facial structure and helping restore selected areas of significant volume loss.

The formulation incorporates 0.3% Lidocaine, a local anaesthetic intended to help reduce injection-related discomfort and improve patient comfort during treatment.

MONALISA® Ultra Type is intended for appropriately qualified professionals with advanced competence in dermal filler procedures, facial anatomy and complication management.

Pack Contents

Each pack contains:

• 1 × 1ml pre-filled syringe of MONALISA® Ultra Type with Lidocaine

• Cross-linked Hyaluronic Acid: 24mg/ml

• Lidocaine: 0.3%

• Particle size: 900µm

• 1 × 25GTW needle

• 1 × 27GTW needle

• Sterile, sealed professional-use packaging

Total Volume: 1ml

Always check the individual product packaging, supplied needle specifications, manufacturer labelling and current Instructions for Use before administration.

Product CompositionCross-Linked Hyaluronic Acid – 24mg/ml

MONALISA® Ultra Type contains highly purified cross-linked Hyaluronic Acid at a concentration of 24mg/ml.

The formulation is designed to support:

• Deep facial volume restoration

• Structural tissue support

• Facial projection

• Contour definition

• Soft tissue augmentation

• Gel stability

• Volume retention

Cross-linking helps improve the stability and persistence of Hyaluronic Acid within the treated tissue compared with non-cross-linked formulations.

Lidocaine – 0.3%

The formulation contains 0.3% Lidocaine, a local anaesthetic incorporated into the gel to help reduce injection-related discomfort.

Patients with known hypersensitivity to Lidocaine or other relevant product components must be appropriately assessed before treatment.

900µm HA Particle Specification

MONALISA® Ultra Type features a 900µm particle specification, making it the largest-particle formulation within the core MONALISA® range.

Its larger-particle, dense gel characteristics are intended to support structural augmentation and volume restoration in appropriate treatment areas.

MONALISA® Filler Technology

The MONALISA® dermal filler range is developed by GENOSS using Hyaluronic Acid manufacturing and cross-linking technology to create injectable gels with different particle characteristics for different aesthetic treatment objectives.

Highly Purified Hyaluronic Acid

GENOSS describes the MONALISA® range as containing highly purified Hyaluronic Acid developed for professional injectable aesthetic applications.

Cross-Linked HA Technology

The cross-linked gel matrix is designed to support gel stability, structural performance and persistence within the treated tissue.

Controlled Particle Characteristics

The core MONALISA® range incorporates progressively different particle specifications:

• Soft Type: 200µm

• Mild Type: 400µm

• Hard Type: 600µm

• Ultra Type: 900µm

These formulations are positioned for different treatment objectives, from superficial correction through to deeper structural augmentation.

High-Density Gel Characteristics

Ultra Type's dense gel is designed to provide structural support, projection and volume retention within appropriate treatment areas.

Lidocaine-Containing Formulation

The inclusion of 0.3% Lidocaine is intended to improve patient comfort during treatment.

Deep Volume Restoration & Structural Contouring

MONALISA® Ultra Type is designed for professional treatment requirements involving greater volume, projection and structural support.

Its high-density cross-linked HA gel is intended to support:

• Restoration of significant facial volume loss

• Chin contour enhancement

• Jawline definition

• Cheek augmentation

• Mid-face volume support

• Facial profile refinement

• Selected structural contour correction

Unlike Soft or Mild Type, Ultra Type is not primarily intended for superficial fine-line correction or subtle skin smoothing.

Its formulation is positioned for advanced treatment objectives requiring a more substantial volumising and structurally supportive gel.

The suitability of any anatomical area must always be confirmed against the manufacturer's current Instructions for Use.

Key Benefits

• Professional cross-linked Hyaluronic Acid dermal filler

• 24mg/ml HA concentration

• 0.3% Lidocaine

• Large 900µm particle specification

• Largest-particle formulation within the core MONALISA® range

• High-density gel characteristics

• Designed for deep facial augmentation

• Supports significant facial volume restoration

• Provides structural tissue support

• Designed for enhanced projection

• Supports facial contour definition

• May support chin augmentation

• May improve jawline definition

• Suitable for selected cheek augmentation protocols where indicated

• Provides immediate physical volume following appropriate placement

• Cross-linked formulation supports gel stability

• Designed for volume retention

• Manufactured using highly purified Hyaluronic Acid

• Lidocaine-containing formulation helps improve treatment comfort

• Supplied with 25GTW and 27GTW needles

• Supplied in a 1ml pre-filled syringe

• Intended for advanced professional use

Common Treatment Areas

MONALISA® Ultra Type may be considered for facial areas requiring deeper structural support, projection or significant volume restoration.

Potential applications described in the supplied product information include:

• Chin augmentation

• Chin projection

• Jawline contouring

• Mandibular definition

• Cheek augmentation

• Mid-face volume restoration

• Selected temporal volume restoration

• Significant facial volume loss

• Facial profile refinement

• Advanced facial contouring

The supplied information also references selected nasal contouring and augmentation procedures.

Nasal filler treatment is a particularly high-risk procedure because of the region's vascular anatomy and the potential for severe complications, including tissue necrosis and visual loss.

Nasal applications must not be assumed to be authorised or appropriate solely because they appear in distributor literature.

Any proposed treatment must be supported by the manufacturer's current Instructions for Use, appropriate specialist training, patient assessment and suitable complication-management arrangements.

Treatment suitability must always be determined following assessment of facial anatomy, vascular structures, tissue characteristics, facial proportions and individual treatment objectives.

MONALISA® Ultra Type vs Other MONALISA® Fillers

The core MONALISA® range includes formulations with different particle characteristics for different treatment objectives.

MONALISA® Soft Type

Particle Specification: 200µm

Positioned primarily for:

• Fine wrinkle correction

• Superficial facial lines

• Subtle soft tissue enhancement

• Delicate correction where authorised

MONALISA® Mild Type

Particle Specification: 400µm

Positioned primarily for:

• Moderate wrinkle correction

• Lip contour and volume

• Natural facial volume enhancement

• Moderate soft tissue augmentation

MONALISA® Hard Type

Particle Specification: 600µm

Positioned primarily for:

• Deeper wrinkle and fold correction

• Facial volume restoration

• Structural tissue support

• Selected facial contour enhancement

MONALISA® Ultra Type

Particle Specification: 900µm

Positioned primarily for:

• Deep volume restoration

• Structural facial augmentation

• Greater projection

• Advanced facial contouring

• Selected areas of significant volume loss

Product selection must always be based on the manufacturer's current indications, gel characteristics, patient anatomy and professional assessment rather than particle size or HA concentration alone.

Professional Treatment Considerations

MONALISA® Ultra Type is intended for administration by appropriately qualified and trained professionals with advanced competence in dermal filler procedures and facial anatomy.

Treatment planning should include:

• Comprehensive patient consultation

• Review of medical history

• Detailed facial assessment

• Evaluation of soft tissue characteristics

• Assessment of facial proportions and symmetry

• Assessment of regional vascular anatomy

• Review of previous aesthetic treatments

• Assessment of contraindications

• Discussion of realistic treatment expectations

• Explanation of potential adverse effects and complications

• Appropriate documented informed consent

Published product specifications position Ultra Type for deeper treatment planes.

The precise treatment depth and technique must always be determined according to the anatomical area, individual patient assessment, the manufacturer's current Instructions for Use and appropriate specialist training.

Needle or cannula selection, product volume and placement must be individually determined by the treating practitioner.

MONALISA® Ultra Type should not be administered using a generic injection protocol without careful consideration of individual facial and vascular anatomy.

Treatment Review & Maintenance

The supplied product information describes an initial treatment followed by professional reassessment.

A clinical review may commonly be considered approximately 2–4 weeks following treatment, according to practitioner protocol and individual patient requirements.

Additional correction should only be considered following appropriate clinical review.

Maintenance requirements will depend on:

• Treatment area

• Product persistence

• Individual anatomy

• Patient metabolism

• Facial movement

• Tissue characteristics

• Previous treatment response

• Individual aesthetic objectives

Treatment intervals and product volumes must always be determined through professional assessment and the manufacturer's current guidance.

Results & Longevity

MONALISA® Ultra Type is designed to provide an immediate volumising and structurally supportive effect following appropriate administration.

Potential treatment outcomes may include:

• Improved facial volume

• Enhanced contour definition

• Improved projection

• Greater structural support

• Improved facial profile

• Correction of selected volume deficiencies

• Improved facial proportions

Initial swelling may temporarily influence the appearance of the treated area and should be considered when assessing early results.

As treatment-related swelling subsides, the final contour may become more apparent.

Professional product information commonly describes MONALISA® Ultra Type as a longer-lasting volumising formulation, with results reported at approximately 12 months or longer.

This is a reported estimate rather than a guaranteed duration.

Individual longevity may vary according to:

• Treatment area

• Product volume

• Administration technique

• Patient metabolism

• Facial movement

• Patient age

• Lifestyle factors

• Tissue characteristics

• Individual biological response

Maintenance treatment may be considered following professional reassessment where appropriate.

Storage & Handling

Store MONALISA® Ultra Type according to the manufacturer's current storage recommendations.

To maintain product integrity:

• Keep the product within its original packaging until required.

• Follow the manufacturer's specified storage conditions.

• Protect from inappropriate environmental exposure.

• Inspect the syringe and packaging before use.

• Check the batch number and expiry date.

• Verify product authenticity and traceability.

• Do not use if the sterile packaging is damaged.

• Do not use if the syringe appears compromised.

• Do not use after the stated expiry date.

The product should be handled using appropriate aseptic procedures.

Each syringe is intended for single use only.

Important Information

MONALISA® Ultra Type with Lidocaine is intended strictly for use by appropriately qualified and trained medical or aesthetic professionals.

Advanced professional knowledge of the following is essential:

• Facial anatomy

• Facial vascular anatomy

• Dermal filler administration

• Appropriate treatment planes

• Patient selection

• Aseptic technique

• Complication prevention

• Vascular compromise recognition

• Emergency management

• Dermal filler complication management

Patient Assessment & Contraindications

Treatment should only proceed following a full patient consultation, medical assessment and appropriate informed consent.

Treatment suitability must be assessed according to the manufacturer's current Instructions for Use.

Factors requiring particular consideration include:

• Active infection or inflammation within the proposed treatment area

• Known hypersensitivity to Hyaluronic Acid

• Known hypersensitivity to Lidocaine or other product components

• Pregnancy or breastfeeding

• Relevant uncontrolled medical conditions

• Previous filler treatments within the proposed treatment area

• Other contraindications identified during professional assessment

This list is not exhaustive and does not replace the manufacturer's official contraindications.

Potential Side Effects

Temporary treatment-related effects may include:

• Redness

• Swelling

• Bruising

• Tenderness

• Localised discomfort

• Temporary firmness

• Injection-site sensitivity

• Localised irregularity

Serious Complications

More serious complications associated with injectable dermal filler procedures may include:

• Infection

• Vascular compromise or occlusion

• Tissue ischaemia or necrosis

• Delayed inflammatory reactions

• Nodules

• Product migration

• Persistent contour irregularities

• Visual impairment or blindness associated with vascular complications

Higher-risk anatomical areas, including the nose, require particular caution and advanced specialist competence.

Practitioners must be appropriately trained in the prevention, recognition and management of filler-related complications, including emergency escalation where required.

Patients should receive appropriate written aftercare information and clear instructions regarding symptoms requiring urgent medical attention.

Always consult the manufacturer's current Instructions for Use for complete indications, contraindications, precautions, warnings, administration guidance and potential adverse events.

Do not use if:

• The sterile packaging is damaged or compromised

• The syringe appears damaged

• The product has passed its expiry date

• Product integrity is in doubt

• Product authenticity cannot be verified

For appropriately qualified professional use only.